Currus Biologics key facts
as of Oct 2026- Developer of CAR-T cell therapies designed to treat solid cancers.
- Currus Biologics is valued at approximately $21.6M as of Oct 2026 (last reported valuation).
- It has raised $19.3M; the latest was Later Stage VC ($11.6M) in Oct 2025.
- Notable investors include Main Sequence Ventures, Brandon Capital, ANDHealth, Brandon Biocatalyst, Peter Maccallum Cancer Centre — 6 tracked in total.
- Status: Privately Held (backing).
Currus Biologics's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch Currus Biologics: the Monday email on marks, rounds and moves
Currus Biologics funding rounds
No funding rounds for Currus Biologics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Currus Biologics
6Currus Biologics valuation
Currus Biologics's last reported valuation was $21.6 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
Currus Biologics investors
6 investors are on record for Currus Biologics, including Main Sequence Ventures, Brandon Capital, ANDHealth and Brandon Biocatalyst.
About Currus Biologics
Developer of CAR-T cell therapies designed to treat solid cancers. The company specializes in bispecific antigen-presenting and T-cell engagers for the treatment of breast, colon, pancreatic, and prostate cancers to create chimeric antigen receptors that kill cancer cells with targeted and effective therapy, enabling patients to receive treatment for solid tumor indications.
- Sector
- Healthcare
- HQ
- Melbourne, Australia
- Founded
- 2020
- Employees
- 10
- Website
- currusbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.